NeuroMetrix, Inc. Announces Date for 2009 First Quarter Financial Results Conference Call

NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2009 first quarter financial results before the opening of the market on Wednesday, May 6, 2009. The Company's management team will host a conference call and webcast at 10:00 A.M. Eastern time, on the same day, to discuss the Company's financial results for the first quarter ended March 31, 2009 and to discuss business and financial developments and trends affecting the Company.

The conference call may be accessed in the United States by dialing 800-638-4817 and using the confirmation code 44139479. Internationally, the conference call may be accessed by dialing 617-614-3943 and using the same confirmation code. The webcast, along with the earnings press release and accompanying condensed financial statements, will be accessible from the Company's website at www.neurometrix.com under the "Investors" tab.

A replay of the conference call will be available starting two hours after the call by dialing 888-286-8010, domestically and 617-801-6888, internationally. The confirmation code to access the replay is 45211200. The replay will be available for three months after the conference call.

About NeuroMetrix

NeuroMetrix is a science-based medical device company advancing patient care through the development and commercialization of innovative products that aid physicians in the assessment, treatment, and repair of peripheral nerve and spinal cord injuries and disorders, and that provide regional anesthesia and pain control. To date, our focus has been primarily on the assessment of neuropathies. Neuropathies affect the peripheral nerves and parts of the spine and are frequently caused by or associated with carpal tunnel syndrome, diabetes, sciatica, and other clinical disorders. We market systems for the performance of nerve conduction studies and needle electromyography procedures.

Our product pipeline includes a system designed to deliver pharmacologic agents such as anesthetics and corticosteroids in close proximity to nerves for regional anesthesia, pain control and the treatment of focal neuropathies. We are also developing neurostimulation-based devices that promote nerve fiber regeneration in acute peripheral nerve and spinal cord injuries.